Savara Inc (NASDAQ:SVRA) Shares Sold by Algert Global LLC

Algert Global LLC cut its holdings in Savara Inc (NASDAQ:SVRA) by 48.1% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 123,968 shares of the company’s stock after selling 114,839 shares during the quarter. Algert Global LLC owned about 0.08% of Savara worth $526,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. CANADA LIFE ASSURANCE Co purchased a new position in Savara in the 1st quarter valued at $35,000. Choreo LLC purchased a new position in Savara during the 2nd quarter worth $59,000. DRW Securities LLC acquired a new stake in shares of Savara in the 2nd quarter worth $62,000. Principal Financial Group Inc. boosted its holdings in shares of Savara by 64.4% in the second quarter. Principal Financial Group Inc. now owns 17,795 shares of the company’s stock valued at $72,000 after acquiring an additional 6,973 shares in the last quarter. Finally, Profund Advisors LLC acquired a new position in shares of Savara during the second quarter worth about $105,000. 87.93% of the stock is owned by hedge funds and other institutional investors.

Savara Price Performance

SVRA stock opened at $3.36 on Friday. The firm has a 50 day moving average of $3.66 and a 200-day moving average of $4.08. The company has a market cap of $576.64 million, a price-to-earnings ratio of -7.81 and a beta of 1.02. The company has a current ratio of 17.70, a quick ratio of 17.70 and a debt-to-equity ratio of 0.13. Savara Inc has a 12-month low of $2.82 and a 12-month high of $5.70.

Savara (NASDAQ:SVRA) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.11) earnings per share for the quarter, meeting the consensus estimate of ($0.11). As a group, equities analysts expect that Savara Inc will post -0.45 EPS for the current fiscal year.

Analyst Ratings Changes

SVRA has been the subject of a number of recent analyst reports. JMP Securities restated a “market outperform” rating and issued a $9.00 price objective on shares of Savara in a research report on Tuesday, October 1st. Evercore ISI reissued an “in-line” rating and issued a $5.00 price target (down from $7.00) on shares of Savara in a report on Wednesday, November 13th. Finally, HC Wainwright dropped their price objective on Savara from $10.00 to $6.00 and set a “buy” rating on the stock in a report on Wednesday, November 13th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $10.17.

Insider Activity

In other Savara news, Director Joseph S. Mccracken acquired 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 19th. The shares were acquired at an average cost of $2.95 per share, for a total transaction of $59,000.00. Following the transaction, the director now directly owns 210,837 shares of the company’s stock, valued at approximately $621,969.15. This represents a 10.48 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 5.13% of the company’s stock.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.